Evidence map›Paper›PMID 38187626›Full record

ArticlebioRxiv : the preprint server for biology2024

Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.

Keene L Abbott, Ahmed Ali, Bradley I Reinfeld, Amy Deik, Sonu Subudhi, Madelyn D Landis, Rachel A Hongo, Kirsten L Young, Tenzin Kunchok, Christopher S Nabel and 11 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Keene L AbbottDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ahmed AliKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Bradley I ReinfeldMedical Scientist Training Program, Vanderbilt University, Nashville, TN, USA.
Amy DeikBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Sonu SubudhiSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5937-1880
Madelyn D LandisDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Rachel A HongoDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Kirsten L YoungDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Tenzin KunchokWhitehead Institute for Biomedical Research, Cambridge, MA, USA.
Christopher S NabelKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Kayla D CrowderWhitehead Institute for Biomedical Research, Cambridge, MA, USA.
Johnathan R KentDepartment of Surgery, University of Chicago Medicine, Chicago, IL, USA.
Maria Lucia L MadariagaDepartment of Surgery, University of Chicago Medicine, Chicago, IL, USA.
Rakesh K JainSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Kathryn E BeckermannDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Caroline A LewisWhitehead Institute for Biomedical Research, Cambridge, MA, USA.
Clary B ClishBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-8259-9245
Alexander MuirBen May Department of Cancer Research, University of Chicago, Chicago, IL, USA.
W Kimryn RathmellDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Jeffrey C RathmellDepartment of Pathology, Microbiology and Immunology, VUMC, Nashville, TN, USA.ORCID 0000-0002-4106-3396
Matthew G Vander HeidenDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6702-4192
Broad Institute · USVanderbilt University Medical Center · USHarvard University · USUniversity of Chicago · USVanderbilt-Ingram Cancer CenterWhitehead Institute for Biomedical Research · USUniversity of Massachusetts Chan Medical School · USVanderbilt University · US

Funding

PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Elizabeth Austen Lawson, Takara Leah Stanley · 1994 to 2026
$31.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell CarcinomaR01CA217987 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2018 to 2026
$4.3M
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1M
Reprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9M
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3M
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2M
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2R01NS118929 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2021 to 2025
$2.0M
Metabolic Contributions of Individual Cellular Compartments to the Diversity of the Tumor Microenvironment in Renal Cell CarcinomaF30CA247202 · NCI · VANDERBILT UNIVERSITY · PI REINFELD, BRADLEY · 2021 to 2023
$107k
NCI NIH HHS F30 CA247202NCI NIH HHS F31 CA271787NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA217987NCI NIH HHS R01 CA259253NCI NIH HHS R35 CA242379NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA224348NCI NIH HHS U01 CA261842NIDDK NIH HHS P30 DK040561NIGMS NIH HHS T32 GM007287NIGMS NIH HHS T32 GM007347NINDS NIH HHS R01 NS118929
6 · The paper itself

Abstract

The tumor microenvironment is a determinant of cancer progression and therapeutic efficacy, with nutrient availability playing an important role. Although it is established that the local abundance of specific nutrients defines the metabolic parameters for tumor growth, the factors guiding nutrient availability in tumor compared to normal tissue and blood remain poorly understood. To define these factors in renal cell carcinoma (RCC), we performed quantitative metabolomic and comprehensive lipidomic analyses of tumor interstitial fluid (TIF), adjacent normal kidney interstitial fluid (KIF), and plasma samples collected from patients. TIF nutrient composition closely resembles KIF, suggesting that tissue-specific factors unrelated to the presence of cancer exert a stronger influence on nutrient levels than tumor-driven alterations. Notably, select metabolite changes consistent with known features of RCC metabolism are found in RCC TIF, while glucose levels in TIF are not depleted to levels that are lower than those found in KIF. These findings inform tissue nutrient dynamics in RCC, highlighting a dominant role of non-cancer driven tissue factors in shaping nutrient availability in these tumors.

Identifiers

PMID38187626
PMCPMC10769456
OpenAlexW4390165134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.